title: A newer immunoglobulin intravenous (IGIV) - Gammagard liquid 10%: evaluation of efficacy, safety, tolerability and impact on patient care.
abstract: BACKGROUND
  Even though all immunoglobulin intravenous (IGIV) end products have high IgG concentrations, variations in manufacturing processes lead to unique product characteristics.
  
  
  OBJECTIVE
  Solvent/detergent-treated IGIV (IGIV-S/D) liquid 10% (Gammagard or Kiovig liquid) is one of the newer products, and this article will discuss and compare its efficacy, safety, tolerability and effect on patient care.
  
  
  METHODS
  The search terms 'immunoglobulin,' 'IGIV,' 'IVIG,' and 'liquid' were entered into PubMed/Medline and Google for the literature search in preparation of this manuscript. Additional references were screened from researched literature.
  
  
  CONCLUSIONS
  Gammagard liquid 10% has shown significant activity in primary immunodeficiency and immune thrombocytopenic purpura. It is a sugar- and sodium-free product with improved safety, tolerability and convenience. Overall, Gammagard liquid is a valuable addition to available therapies that has utility in life-threatening and complicated diseases, and its use will continue to grow.
authors.affiliation: Associate Professor of Pharmacy Practice/Hematology-Oncology Clinical Pharmacist Texas Tech University Health Sciences Center, School of Pharmacy/Veterans Affairs North Texas Healthcare System, Dallas, TX 75216, USA. sachin.shah@ttuhsc.edu
authors.forename: Sachin R
authors.initials: SR
authors.lastname: Shah
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D005591:Chemical Fractionation / Q000379:methods; D002648:Child; D017326:Clinical Trials, Phase III as Topic / Q000706:statistics & numerical data; D000075202:Contraindications; D004333:Drug Administration Routes; D004340:Drug Contamination; D005260:Female; D005998:Glycine; D006261:Headache / Q000209:etiology; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage* / Q000009:adverse effects / Q000302:isolation & purification / Q000493:pharmacokinetics / Q000627:therapeutic use; D007153:Immunologic Deficiency Syndromes / Q000628:therapy; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D010949:Plasma / Q000276:immunology; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000628:therapy; D012996:Solutions
chemical_list: D016756:Immunoglobulins, Intravenous; D012996:Solutions; D005998:Glycine